Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Public ClinicalTrials.gov record NCT04116437. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.
Study identification
- NCT ID
- NCT04116437
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 96 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2019 (Actual)
- Primary completion
- Jan 9, 2026 (Actual)
- Completion
- Jan 9, 2026 (Actual)
- Last update posted
- Jan 28, 2026
2019 – 2026
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Centers (Williams) Usor | Aurora | Colorado | 80012-5405 | — |
| Christiana Care | Newark | Delaware | 19713-2055 | — |
| Scri Florida Cancer Specialists South | Fort Myers | Florida | 33901-8108 | — |
| St Century Oncology | Jacksonville | Florida | 32204-1128 | — |
| Scri Florida Cancer Specialists North | St. Petersburg | Florida | 33705-1449 | — |
| Healthcare Research Network Iii, Llc | Flossmoor | Illinois | 60422-2067 | — |
| Minnesota Oncology Burnsville Clinic | Burnsville | Minnesota | 55337-6749 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169-3321 | — |
| Summit Medical Group | Florham Park | New Jersey | 07932-1049 | — |
| Morristown Medical Center | Morristown | New Jersey | 07960-6136 | — |
| Clinical Research Alliance, Inc | Westbury | New York | 11590-5119 | — |
| Oncology Associates of Oregon Willamette Valley Cancer Center | Eugene | Oregon | 97401 | — |
| St Lukes University Health Network | Fountain Hill | Pennsylvania | 18015-1153 | — |
| Abington Hematology Oncology Associates | Horsham | Pennsylvania | 19044-2331 | — |
| Tennessee Oncology, Pllc Nashville | Nashville | Tennessee | 37203 | — |
| Texas Oncology Amarillo | Amarillo | Texas | 79106-1781 | — |
| Texas Oncology Tyler Longview | Austin | Texas | 78705-1163 | — |
| Baylor Research Institute | Dallas | Texas | 75246-2079 | — |
| Texas Oncology McAllen South Second Street | McAllen | Texas | 78503 | — |
| Us Oncology Virginia Cancer Specialists, Pc | Fairfax | Virginia | 22031-4629 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502-2800 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109-4433 | — |
| Medical Oncology Associates | Spokane | Washington | 99208-1129 | — |
| Ssm Health Cancer Care Dean Medical Center | Madison | Wisconsin | 53717-1959 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04116437, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04116437 live on ClinicalTrials.gov.